Featured Insights
December 15, 2025
Podcast
The Latham team unpacks the FDA’s recent actions on the Commissioner’s National Priority Voucher program, the plausible mechanism pathway, and biosimilars — and what they could mean for development timelines, pricing, and market access.
December 15, 2025
Podcast
Partner Betty Huber speaks with Devon Leahy, Global Head of Sustainability at L Catterton, about building a sustainability program from the ground up across a US$37 billion consumer-focused portfolio.
December 15, 2025
Newsletter
Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law.